undamentalytics Newsletter
Sign in

Ocular Therapeutix, Inc income statement

In fiscal 2025, Ocular Therapeutix, Inc reported revenue of $52.0m, down 18.5% on the year before, operating income of −$270m (a -519.8% margin) and net income of −$266m, or −$1.42 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue012222417445158645252
Cost of revenue————0022455677
Gross profit————12215394753584545
Research and development1219272731374129505361128197224
Selling and marketing12471752427354041425460
General and administrative1791116192223323234616476
Operating income−14−27−38−43−62−59−86−63−78−79−82−172−270−314
Interest expense012222677711141211
Income tax0000000000000—
Net income−14−29−40−45−63−60−86−156−7−71−81−194−266−301
Diluted EPS−$1.40−$2.69−$1.71−$1.80−$2.20−$1.57−$1.91−$2.56−$0.98−$0.97−$1.02−$1.22−$1.42−$1.41
Diluted shares (average)10m11m23m25m29m38m45m61m82m83m86m158m187m214m
EBITDA−13−27−37−42−60−57−83−60−76−77−79−168−266−308

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GOSS vs OCULOCUL vs SIGAOCUL vs TNGXEDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ocular Therapeutix, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ocular Therapeutix, Inc.